3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Breast
2
Thoracic
1
NET
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
36
Lung Neoplasms
7
Brain Neoplasms
3
Thyroid Neoplasms
2
Neoplasms
2
Gastrointestinal Neoplasms
2
Breast Neoplasms
2
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sexual Dysfunction, Physiological
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 2a
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Genomic Instability
1
Gastrointestinal Diseases
1
Eunuchism
1
Erectile Dysfunction
1
Disease Resistance
1
Interventions
pembrolizumab
39
Gemcitabine
30
Nivolumab
15
Cetuximab
13
Carboplatin
13
Cyclophosphamide
12
Cisplatin
12
Irinotecan
10
Docetaxel
10
130-nm albumin-bound paclitaxel
10
Trastuzumab
8
Magnetic Resonance Spectroscopy
8
fludarabine
7
aldesleukin
7
Paclitaxel
7
Drug Therapy
7
Bevacizumab
7
Taxes
6
Specimen Handling
6
Fluorouracil
6
Capecitabine
6
Albumin-Bound Paclitaxel
6
sargramostim
5
Pemetrexed
5
Oxaliplatin
5
Ipilimumab
5
spartalizumab
4
durvalumab
4
Standard of Care
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
alectinib
×
Thoracic
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts